20981340

Source:http://linkedlifedata.com/resource/pubmed/id/20981340

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists.
Subject	Predicate	Object	Context
pubmed-article:20981340	rdf:type	pubmed:Citation	lld:pubmed
pubmed-article:20981340	lifeskim:mentions	umls-concept:C1422190	lld:lifeskim
pubmed-article:20981340	pubmed:dateCreated	2010-10-28	lld:pubmed
pubmed-article:20981340	pubmed:abstractText	The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.	lld:pubmed
pubmed-article:20981340	pubmed:language	eng	lld:pubmed
pubmed-article:20981340	pubmed:journal	http://linkedlifedata.com/r...	lld:pubmed
pubmed-article:20981340	pubmed:status	PubMed-not-MEDLINE	lld:pubmed
pubmed-article:20981340	pubmed:issn	2042-0064	lld:pubmed
pubmed-article:20981340	pubmed:author	pubmed-author:SilvermanStua...	lld:pubmed
pubmed-article:20981340	pubmed:issnType	Electronic	lld:pubmed
pubmed-article:20981340	pubmed:volume	2010	lld:pubmed
pubmed-article:20981340	pubmed:owner	NLM	lld:pubmed
pubmed-article:20981340	pubmed:authorsComplete	Y	lld:pubmed
pubmed-article:20981340	pubmed:pagination	941419	lld:pubmed
pubmed-article:20981340	pubmed:year	2010	lld:pubmed
pubmed-article:20981340	pubmed:articleTitle	Sclerostin.	lld:pubmed
pubmed-article:20981340	pubmed:affiliation	Cedars-Sinai, UCLA, OMC Clinical Research Center, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA.	lld:pubmed
pubmed-article:20981340	pubmed:publicationType	Journal Article	lld:pubmed